New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 13, 2014
04:55 EDTLIFE, LIFE, LIFE, CYCC, CYCC, CYCC, BLUE, BLUE, BLUE, PJC, PJC, PJC, STEM, STEM, STEM, ATHX, ATHX, ATHX, NBS, NBS, NBS, ONVO, ONVO, ONVO, CYTX, CYTX, CYTX, ISCO, ISCO, ISCOEBD Group to hold a conference
Biotech Showcase 2014 is being held in San Francisco on January 13-15.
News For LIFE;CYTX;ONVO;NBS;ATHX;STEM;PJC;BLUE;CYCC;ISCO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 29, 2015
16:18 EDTBLUEbluebird bio announces retirement of CSO Mitchell Finer
Subscribe for More Information
January 28, 2015
11:55 EDTCYTXCytori Therapeutics management to meet with Roth Capital
Subscribe for More Information
January 26, 2015
10:00 EDTPJCOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: American Axle (AXL) upgraded to Overweight from Neutral at JPMorgan... Bed Bath & Beyond (BBBY) upgraded to Outperform from Perform at Oppenheimer... DRDGOLD (DRD) upgraded to Neutral from Underweight at JPMorgan... DealerTrack (TRAK) upgraded to Buy from Hold at Stifel... DreamWorks Animation (DWA) upgraded to Buy from Neutral at B. Riley... First Niagara (FNFG) upgraded to Buy from Hold at Jefferies... Fortinet (FTNT) upgraded to Buy from Neutral at Citigroup... Garmin (GRMN) upgraded at RBC Capital... Harmony Gold (HMY) upgraded to Overweight from Neutral at JPMorgan... Invesco (IVZ) upgraded to Positive from Neutral at Susquehanna... Kansas City Southern (KSU) upgraded at Raymond James... McDonald's (MCD) upgraded to Overweight from Equal Weight at Stephens... Melco Crown (MPEL) upgraded to Buy from Hold at Union Gaming... Monro Muffler (MNRO) upgraded to Neutral from Reduce at SunTrust... Pier 1 Imports (PIR) upgraded to Outperform from Perform at Oppenheimer... Piper Jaffray (PJC) upgraded to Neutral from Underperform at Macquarie... Randgold (GOLD) upgraded to Overweight from Neutral at JPMorgan... Rockwell Collins (COL) upgraded to Buy from Hold at Argus... Telefonica (TEF) upgraded to Neutral from Underperform at BofA/Merrill... Triumph Group (TGI) upgraded at RBC Capital... Unilever (UL) upgraded to Buy from Underperform at BofA/Merrill... WWE (WWE) upgraded to Neutral from Underperform at Macquarie.
07:26 EDTPJCPiper Jaffray upgraded to Neutral from Underperform at Macquarie
Subscribe for More Information
January 22, 2015
11:27 EDTCYTXCytori Therapeutics management to meet with Roth Capital
Subscribe for More Information
07:43 EDTBLUEbluebird bio reinstated with a Buy at BofA/Merrill
Subscribe for More Information
07:15 EDTATHXAthersys announces GBP 2M grant to support Phase 2a clinical study of MultiStem
Subscribe for More Information
January 21, 2015
12:27 EDTBLUEbluebird bio price target raised to $146 from $94 at Wedbush
Subscribe for More Information
08:51 EDTPJCArena Pharma sells 21M shares to Leucadia's Jefferies and Piper Jaffray
Arena Pharmaceuticals (ARNA) has sold 21M shares of common stock to Jefferies, a subsidiary of Leucadia (LUK) and to Piper Jaffray (PJC) as underwriters for its previously announced public offering. The offering is expected to close on or about January 26. In addition, Arena has granted the underwriters a 30-day option to purchase up to an aggregate of 3M additional shares of common stock. Arena anticipates using the net proceeds from the offering for the clinical and preclinical development of drug candidates, for discovery research for new drug candidates, and for general corporate purposes.
January 20, 2015
16:25 EDTCYTXCytori says STAR trial will begin enrolling in 2015
Subscribe for More Information
13:21 EDTBLUECAR T-Cell therapy drug stocks down sharply following NY Times story
Shares of biotechnology companies that are developing chimeric antigen receptor T cells or CAR T therapy drugs are falling sharply after a New York Times story titled "Riding High, Biotech Firms Remain Wary." WHAT'S NEW: Over the weekend, the New York Times published the story that struck a cautionary tone on the CAR-T therapy drugs. In this form of cancer treatment the patients own immune system cells are genetically manipulated to battle tumors. The New York Times story noted that there were some notable outcomes in the treatment of leukemia and lymphoma with the CAR T treatments but highlighted that the "technique is still early in development and can cause severe side effects." WHAT'S NOTABLE. Early last week, Intrexon (XON) and its oncology partner, ZIOPHARM Oncology (ZIOP), announced an exclusive licensing agreement with The University of Texas MD Anderson Cancer Center, including an exclusive sub-licensing agreement through MD Anderson for intellectual property developed at the University of Minnesota for the development of non-viral adoptive cellular cancer immunotherapies. Both companies' shares were up sharply following the announcement ZIOPHARM was up around 55% and Intrexon up over 30% the day following the announcement. PRICE ACTION: Shares of drug companies in the space are sharply lower in midday trading, with ZIOPHARM Oncology and Kite Pharma (KITE) each down over 9%, Intrexon down almost 12%, and Bellicum Pharmaceutical (BLCM) and bluebird bio (BLUE) each down almost 5%. Reference Link
08:40 EDTCYTXCytori Therapeutics price target raised to $6 from $3.50 at Roth Capital
Roth Capital increased its price target on Cytori after the company received final FDA approval for a clinical trial of its treatment for scleroderma., and the firm attended an event hosted by the company with a scleroderma expert. Roth says that the expert highlighted the unmet medical need in scleroderma as well its significant morbidity and mortality. The firm expects the company's visibility to improve this year, and it keeps a Buy rating on the stock.
07:33 EDTNBSNeoStem receives drug manufacture license for Irvine, CA facility
NeoStem announced that the State of California's Department of Public Health, Food and Drug Branch has completed its review of NeoStem's manufacturing and control processes at its Irvine, California cGMP facility for the production of eltrapuldencel-T and has issued NeoStem a manufacturing license permitting NeoStem to manufacture drugs from this facility, including the manufacture of eltrapuldencel-T for clinical trial use. Eltrapuldencel-T is the company's patient-specific targeted cancer immunotherapy under investigation for the treatment of Stage IV or recurrent Stage III metastatic melanoma.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use